Authored by Cello Health, now part of Lumanity
Following the acquisition in 2020 of BresMed and Cello Health by Arsenal Capital Partners (“Arsenal”), a leading private equity firm investing in healthcare and specialty industrials companies, the two organizations are coming together to provide broader support for their biopharmaceutical clients. The combined expertise and capabilities of the two businesses creates a unique combination of solutions to develop and communicate evidence of value to optimize patient access to new therapies.
The joining of BresMed and Cello Health represents a first foundational step in the creation of a new value demonstration focused organization that will continue to expand around the mission of improving patient health by accelerating and optimizing access to effective medical advances.
“By bringing these two organizations together we are enabling a diverse set of industry experts to collaborate to tackle some of the biopharma industries toughest problems.” said Jon Williams, Group CEO. “We are very excited about the innovative new methods and cutting-edge scientific capabilities that both BresMed and Cello will continue to deliver.”
Mark Scott, Group Vice Chair added, “This collaboration of industry, scientific and commercial expertise offers a unique perspective to help expand support for our clients, and continues our ambition to become a world-class company.”
Ron Akehurst, Executive Chair of BresMed also noted: “We are committed to a seamless experience for our clients, and one that is rooted in superior science, cutting-edge methods, and a focus on building successful paths to market for new therapies.”
For more information please firstname.lastname@example.org
BresMed, acquired by Arsenal in February of 2020, is a health economic and outcomes research consultancy that provides health economic solutions to the global pharmaceutical industry. Established in 2006, BresMed has more than 170 employees across offices in the U.K., Ireland, the Netherlands, the U.S., and India who work to support clients with drug, device, and diagnostic products to reach markets at the best possible price. BresMed’s services span the full product development pipeline, from initial portfolio planning, strategy development, and health technology assessment through to post-launch value demonstration in multiple jurisdictions.
Cello Health, acquired by Arsenal in August of 2020, is a global healthcare-focused advisory firm comprised of a set of leading scientific, commercial advisory and digital delivery capabilities. Cello Health currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients. Cello Health enables clients to commercialize, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilizing latest thinking, technology and digital solutions. Cello Health delivers its services from an office network in Europe and USA, with hub offices in New York City, Philadelphia, Boston, New Jersey, London, Berlin, Edinburgh, and Farnham.